Evidence map›Paper›PMID 24386454›Full record

Trial reportPloS one2013

Glaucocalyxin A inhibits platelet activation and thrombus formation preferentially via GPVI signaling pathway.

Wei Li, Xiaorong Tang, Wenxiu Yi, Qiang Li, Lijie Ren, Xiaohui Liu, Chunjun Chu, Yukio Ozaki, Jian Zhang, Li Zhu

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Glaucocalyxin A Attenuates IL-1Disease markers · 2022
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Glaucocalyxin A Ameliorates Myocardial Ischemia-Reperfusion Injury in Mice by Suppression of Microvascular Thrombosis.Medical science monitor : international medical journal of experimental and clinical research · 2016
    Article
  15. Natural Products for Antithrombosis.Evidence-based complementary and alternative medicine : eCAM · 2015
    Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Wei LiCyrus Tang Hematology Center, Soochow University, Suzhou, China.
Xiaorong TangCyrus Tang Hematology Center, Soochow University, Suzhou, China.
Wenxiu YiCyrus Tang Hematology Center, Soochow University, Suzhou, China.
Qiang LiCyrus Tang Hematology Center, Soochow University, Suzhou, China.
Lijie RenCyrus Tang Hematology Center, Soochow University, Suzhou, China.
Xiaohui LiuCyrus Tang Hematology Center, Soochow University, Suzhou, China.
Chunjun ChuCollege of Pharmaceutical Science, Soochow University, Suzhou, China.
Yukio OzakiDepartment of Laboratory Medicine, Faculty of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.
Jian ZhangCollege of Pharmaceutical Science, Soochow University, Suzhou, China.
Li ZhuCyrus Tang Hematology Center, Soochow University, Suzhou, China.
Soochow University · CNUniversity of Yamanashi · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platelets play a pivotal role in atherothrombosis and the antiplatelet agents have been proved to be useful in preventing onset of acute clinical events including myocardial infarction and stroke. Increasing number of natural compounds has been identified to be potential antiplatelet agents. Here we report the antiplatelet effect of glaucocalyxin A (GLA), an ent-diterpenoid that we isolated and purified from the aerial parts of Rabdosia japonica (Burm. f.) var. glaucocalyx (Maxim.) Hara, and investigate the molecular mechanisms by which GLA inhibits platelet activation and thrombus formation. The effect of GLA on platelet activation was measured using platelets freshly isolated from peripheral blood of healthy donors. Results showed that pretreatment of human platelets with lower concentrations of GLA (0.01 μg/ml, 0.1 μg/ml) significantly inhibited platelet aggregation induced by collagen (P<0.001) and CRP (P<0.01), a synthetic GPVI ligand, but not by ADP and U46619. Accordingly, GLA inhibited collagen-stimulated tyrosine phosphorylation of Syk, LAT, and phospholipase Cγ2, the signaling events in collagen receptor GPⅥ pathway. GLA also inhibited platelet p-selectin secretion and integrin activation by convulxin, a GPVI selective ligand. Additionally, GLA was found to inhibit low-dose thrombin-induced platelet activation. Using a flow chamber device, GLA was found to attenuate platelet adhesion on collagen surfaces in high shear condition. In vivo studies showed that GLA administration increased the time for complete occlusion upon vascular injury in mice, but did not extend tail-bleeding time when mice were administered with relatively lower doses of GLA. Therefore, the present results provide the molecular basis for the inhibition effect of GLA on platelet activation and its in vivo effect on thrombus formation, suggesting that GLA could potentially be developed as an antiplatelet and antithrombotic agent.

Indexed as

15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic AcidAdenosine DiphosphateAnimalsAnti-Inflammatory Agents, Non-SteroidalBlood CoagulationBlood PlateletsCollagenDiterpenes, KauraneHumansIsodonMaleMicePlatelet AdhesivenessPlatelet Membrane GlycoproteinsSignal TransductionVasoconstrictor Agents15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic AcidAdenosine DiphosphateAnti-Inflammatory Agents, Non-SteroidalCollagenDiterpenes, Kauraneglaucocalyxin APlatelet Membrane Glycoproteinsplatelet membrane glycoprotein VIVasoconstrictor Agents

Identifiers

PMID24386454
PMCPMC3875551
OpenAlexW2014537724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.